Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels

(2015) Jörg Haupenthal et al.   NEOPLASIA

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains

(2013) S. Picaud et al.   CANCER RESEARCH

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

(2013) M A Dawson et al.   LEUKEMIA

Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation

(2013) Mechthild Krause et al.   RADIOTHERAPY AND ONCOLOGY

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1

(2013) Helen Jayne Susan Stewart et al.   Cancer Medicine

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs

(2012) Channing J. Paller et al.   CANCER RESEARCH

Abstract 1920: Small molecule inhibitor of polo-like kinase 1 (Plk1) causes significant melanoma growth delay and regressionin vivo

(2012) Brian D. Cholewa et al.   CANCER RESEARCH

Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer

(2012) V. S. Nair et al.   CANCER RESEARCH

 p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors

(2012) Mourad Sanhaji et al.   CELL CYCLE

253 Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies

(2012) C. Lanvers-Kaminsky et al.   EUROPEAN JOURNAL OF CANCER

Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

(2012) Galina Tsykunova et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Acute myeloid leukemia in older adults

(2012) Masamitsu Yanada et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Demethylase UTX and Chromatin Remodeler BRM Bind Directly to CBP and Modulate Acetylation of Histone H3 Lysine 27

(2012) F. Tie et al.   MOLECULAR AND CELLULAR BIOLOGY

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid

(2012) Rakel Brendsdal Forthun et al.   PLoS One

   cells making IL-17

(2011) B. Silva-Santos   BLOOD

Abstract 5414: Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors

(2011) Michel D. Wissing et al.   CANCER RESEARCH

Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

(2011) R. H. Medema et al.   CLINICAL CANCER RESEARCH

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Combination of Chemical Genetics and Phosphoproteomics for Kinase Signaling Analysis Enables Confident Identification of Cellular Downstream Targets

(2011) Felix S. Oppermann et al.   MOLECULAR & CELLULAR PROTEOMICS

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

(2011) N Ånensen et al.   ONCOGENE

Utility of mTOR Inhibition in Hematologic Malignancies

(2011) A. Younes et al.   ONCOLOGIST

Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells

(2011) Yu J. Chen et al.   PROTEOMICS

Quantitative Phosphoproteomics Identifies Substrates and Functional Modules of Aurora and Polo-Like Kinase Activities in Mitotic Cells

(2011) A. N. Kettenbach et al.   Science Signaling

Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia

(2011) J Skavland et al.   Blood Cancer Journal

Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) M. F. Fey et al.   ANNALS OF ONCOLOGY

Targeting the "partners in crime"

(2010) C. Pepper   BLOOD

Questions regarding frontline therapy of acute myeloid leukemia

(2010) Hagop Kantarjian et al.   CANCER

A functional link between Polo-like kinase 1 and the mammalian Target-Of-Rapamycin pathway?

(2010) Annelies G. Renner et al.   CELL CYCLE

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Time to Step Out of the Limelight

(2010) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

(2010) Y. Degenhardt et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Clinical proteomics of myeloid leukemia

(2010) Sigrun M Hjelle et al.   Genome Medicine

AML in older patients: Are we making progress?

(2009) Elihu Estey   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

(2009) S. Park et al.   HAEMATOLOGICA

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

(2009) T Ikezoe et al.   LEUKEMIA

Polo-like kinase 1 phosphorylates and regulates Bcl-xL during pironetin-induced apoptosis

(2008) Y Tamura et al.   ONCOGENE